Targeting targeted agents: open issues for clinical trial design

Molecularly targeted agents for the treatment of solid tumors had entered the market in the last 5 years, with a great impact upon both the scientific community and the society. Many randomized phase III trials conducted in recent years with new targeted agents, despite previous data coming from pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bria, Emilio, Di Maio, Massimo, Carlini, Paolo, Cuppone, Federica, Giannarelli, Diana, Cognetti, Francesco, Milella, Michele
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697149/
https://www.ncbi.nlm.nih.gov/pubmed/19463172
http://dx.doi.org/10.1186/1756-9966-28-66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697149/
https://www.ncbi.nlm.nih.gov/pubmed/19463172
http://dx.doi.org/10.1186/1756-9966-28-66

Ejemplares similares